Cwm LLC Sells 1,814 Shares of Koninklijke Philips (NYSE:PHG)

Cwm LLC lessened its stake in shares of Koninklijke Philips (NYSE:PHG) by 10.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,170 shares of the technology company’s stock after selling 1,814 shares during the quarter. Cwm LLC’s holdings in Koninklijke Philips were worth $354,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of PHG. Allworth Financial LP boosted its position in Koninklijke Philips by 113.3% during the 3rd quarter. Allworth Financial LP now owns 3,242 shares of the technology company’s stock valued at $65,000 after acquiring an additional 1,722 shares in the last quarter. Spire Wealth Management boosted its position in Koninklijke Philips by 127.2% during the 3rd quarter. Spire Wealth Management now owns 3,446 shares of the technology company’s stock valued at $69,000 after acquiring an additional 1,929 shares in the last quarter. Bruce G. Allen Investments LLC bought a new stake in Koninklijke Philips during the 4th quarter valued at $140,000. PAX Financial Group LLC purchased a new stake in shares of Koninklijke Philips during the 3rd quarter valued at $199,000. Finally, Contravisory Investment Management Inc. purchased a new stake in shares of Koninklijke Philips during the 4th quarter valued at $200,000. Institutional investors own 13.67% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on PHG. StockNews.com upgraded Koninklijke Philips from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. JPMorgan Chase & Co. upgraded Koninklijke Philips from an “underweight” rating to a “neutral” rating in a report on Tuesday. BNP Paribas lowered Koninklijke Philips from an “outperform” rating to an “underperform” rating in a report on Wednesday, February 7th. Finally, UBS Group upgraded Koninklijke Philips from a “sell” rating to a “neutral” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $19.00.

Koninklijke Philips Stock Performance

Shares of PHG stock opened at $26.56 on Friday. The firm has a market capitalization of $24.66 billion, a price-to-earnings ratio of -27.67, a price-to-earnings-growth ratio of 1.37 and a beta of 0.75. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.20 and a quick ratio of 0.78. The business has a fifty day moving average of $20.95 and a 200 day moving average of $21.12. Koninklijke Philips has a 1 year low of $17.75 and a 1 year high of $29.44.

Koninklijke Philips (NYSE:PHG) last issued its earnings results on Monday, January 29th. The technology company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The company had revenue of $5.45 billion during the quarter, compared to analyst estimates of $5.47 billion. Koninklijke Philips had a positive return on equity of 9.82% and a negative net margin of 4.41%. As a group, research analysts expect that Koninklijke Philips will post 1.53 earnings per share for the current year.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.